* Testing the association between circulating candidate proteins and the level of vascular leakage for three distinct forms of circulatory failure: cardiogenic shock, septic shock, and post-resuscitation syndrome. * Describing immuno-inflammatory profiles associated with massive vascular leakage during those three forms of circulatory failure in humans
Circulatory shocks are responsible for one third of intensive care unit (ICU) admissions (20,000 patients per year in France) and are associated with 40% mortality \[1,2\]. Vascular hyperpermeability (also called vascular leakage) is a major feature of circulatory failure. During systemic inflammatory response syndrome (SIRS), massive vascular leakage affects macro and micro-circulation, and participates in the development of multiple organ failure \[1,3\]. Accordingly, fluid balance (the difference between fluid input and output) correlates independently with mortality during both septic and cardiogenic shock \[4-7\] and controlling capillary leakage was highly beneficial in numerous animal models of circulatory failure \[8-10\]. However, the determinants of vascular leakage remain poorly understood in humans. The purpose of this study is to evaluate the link between circulatory levels of several proteins and the level of vascular leakage, in three distinct types of circulatory shocks.
Study Type
OBSERVATIONAL
Enrollment
380
Hôpital Européen Georges Pompidou
Paris, France
RECRUITINGFluid balance from Day 0 to day 3
(ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,…)
Time frame: Between Day 0 and Day 3
Fluid balance
(ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,…)
Time frame: Day 1, Day 3, Day 7, Day 14
Extra-vascular lung water index
Extra-vascular lung water index (EVLWi, ml/kg) and pulmonary vascular permeability index measured by transpulmonary thermodilution at corresponding time-points
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Serum albuminemia
g/L
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Serum lactatemia
mmoles/L
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Arterial PaO2
(mmHg)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Circulating cytokine inflammatory profile IL-33
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Circulating cytokine inflammatory profile TNF-alpha
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Circulating cytokine inflammatory profile IL-6
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Circulating cytokine inflammatory profile IL-1
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
SOFA score
Association between circulating candidate proteins, the immune-inflammatory profile of the patients and SOFA score
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Catecholamine-free days
Number of days alive without receiving any catecholamine
Time frame: Day 0 to Day 7, Day 30
Ventilatory-free days
Number of days alive without receiving any machenical ventilation, invasive or non-invasive
Time frame: Day 0 to Day 7, Day 30
Renal replacement therapy-free
Number of days alive without receiving any renal replacement therapy
Time frame: Day 0 to Day 7, Day 30
Mortality
Time frame: Day 30